TRANSTHYRETIN-TYPE CARDIAC AMYLOIDOSIS

Clinical trials for TRANSTHYRETIN-TYPE CARDIAC AMYLOIDOSIS explained in plain language.

Never miss a new study

Get alerted when new TRANSTHYRETIN-TYPE CARDIAC AMYLOIDOSIS trials appear

Sign up with your email to follow new studies for TRANSTHYRETIN-TYPE CARDIAC AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New heart drug study aims to halt deadly protein buildup

Disease control Recruiting now

This study is checking if the drug acoramidis can slow down the progression of a serious heart condition called transthyretin cardiac amyloidosis, where abnormal proteins build up in the heart. It will follow 200 patients who are either newly starting the drug or switching from a…

Matched conditions: TRANSTHYRETIN-TYPE CARDIAC AMYLOIDOSIS

Phase: PHASE4 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 20, 2026 14:48 UTC

TRANSTHYRETIN-TYPE CARDIAC AMYLOIDOSIS

Get alerted when new TRANSTHYRETIN-TYPE CARDIAC AMYLOIDOSIS trials appear

New heart drug study aims to halt deadly protein buildup